Intra-Cellular Therapies Inc [ITCI] stock is trading at $127.97, up 0.32%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ITCI shares have gain 0.74% over the last week, with a monthly amount glided 0.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intra-Cellular Therapies Inc [NASDAQ: ITCI] stock has seen the most recent analyst activity on January 31, 2025, when Canaccord Genuity downgraded its rating to a Hold and also boosted its price target to $132 from $119. Previously, Piper Sandler upgraded its rating to Overweight on September 06, 2024, and elevated its price target to $92. On January 03, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $83 on the stock. TD Cowen started tracking the stock assigning a Outperform rating and suggested a price target of $75 on December 11, 2023. Morgan Stanley initiated its recommendation with a Overweight and recommended $80 as its price target on April 20, 2023. Goldman downgraded its rating to Neutral for this stock on August 22, 2022, and downed its price target to $49. In a note dated July 07, 2022, Mizuho initiated an Buy rating and provided a target price of $74 on this stock.
Intra-Cellular Therapies Inc [ITCI] stock has fluctuated between $62.78 and $128.00 over the past year. Currently, Wall Street analysts expect the stock to reach $105.5 within the next 12 months. Intra-Cellular Therapies Inc [NASDAQ: ITCI] shares were valued at $127.97 at the most recent close of the market. An investor can expect a potential drop of -17.56% based on the average ITCI price forecast.
Analyzing the ITCI fundamentals
Intra-Cellular Therapies Inc [NASDAQ:ITCI] reported sales of 613.73M for the trailing twelve months, which represents a growth of 39.00%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.1 and Total Capital is -0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 127.62 points at the first support level, and at 127.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 128.16, and for the 2nd resistance point, it is at 128.34.
Ratios To Look Out For
For context, Intra-Cellular Therapies Inc’s Current Ratio is 7.66. Also, the Quick Ratio is 7.51, while the Cash Ratio stands at 2.8. Considering the valuation of this stock, the price to sales ratio is 22.15, the price to book ratio is 11.85.
Transactions by insiders
Recent insider trading involved Mates Sharon, Chairman and CEO, that happened on Dec 04 ’24 when 51000.0 shares were sold. Chairman and CEO, Mates Sharon completed a deal on Dec 05 ’24 to sell 51697.0 shares. Meanwhile, Officer Mates Sharon bought 51697.0 shares on Dec 05 ’24.
